Talquetamab Plus Daratumumab Combination Reduces Progression Risk by Up to 72% in Phase 3 Relapsed Multiple Myeloma Trial

Why It Matters

The data position a GPRC5D‑targeted bispecific as a potentially new standard for earlier‑line RRMM, promising longer survival and deeper responses that could reshape treatment sequencing and market dynamics.

Key Takeaways

• 24‑mo PFS 81.3% vs 51.2% with DPd regimen
• Overall survival 89.2% versus 79.1% at two years
• MRD‑negative ≥CR achieved in 52.3% versus 15.9% control
• Risk of progression reduced by up to 72%, death by 53%
• CRS observed in 68% of patients, mostly grade 1‑2

Pulse Analysis

Multiple myeloma has evolved from a terminal disease to a chronic condition, yet patients inevitably relapse after each line of therapy. The emergence of bispecific T‑cell engagers targeting novel antigens such as GPRC5D offers a mechanistic shift away from the BCMA‑centric paradigm that has dominated recent approvals. By redirecting patient T cells to a receptor largely absent from normal B cells, talquetamab minimizes off‑target B‑cell depletion while delivering potent cytotoxicity, a balance that is especially valuable in earlier‑line settings where preserving immune competence matters.

The MonumenTAL‑3 results are striking not only for the magnitude of hazard‑ratio reductions—0.28 for progression and 0.47 for death—but also for the depth of response. Over half of treated patients achieved MRD‑negative status at a 10⁻⁵ threshold, a benchmark associated with durable remission in myeloma. These outcomes suggest that integrating a GPRC5D bispecific with daratumumab could become a preferred backbone, potentially displacing the current DPd standard and influencing upcoming guideline updates. Payers will also note the improved overall survival, which may justify the higher acquisition costs of combination biologics.

Safety remains a critical consideration. While cytokine release syndrome occurred in two‑thirds of participants, most events were grade 1‑2 and manageable with standard protocols. Unique on‑target effects—taste alteration and weight loss—reflect GPRC5D expression in epithelial tissues but rarely led to discontinuation. As Johnson & Johnson advances a supplemental BLA in the U.S. and a Type II variation in the EU, the oncology community will watch regulatory reviews closely, anticipating a new therapeutic option that could extend both quantity and quality of life for thousands of RRMM patients.